Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,817 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Disease, Pulmonary Clear all
Completed Phase 2 Interventional Results available

Citrulline in Severe Sepsis

NCT01474863
View directory record Official record
Conditions
Severe Sepsis, Acute Lung Injury
Interventions
High Dose Citrulline, Placebo, Low Dose Citrulline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 16, 2026, 10:57 AM EDT
Active, not recruiting Not applicable Interventional

Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules

NCT06638398
View directory record Official record
Conditions
Lung Neoplasm
Interventions
Computed Tomography, Diagnostic Procedure, Best Practice, Electronic Health Record Review
Procedure · Device · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
35 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • St Louis, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 16, 2026, 10:57 AM EDT
Completed Not applicable Interventional

Discharge ALERT: Quality Improvement Initiative

NCT00853463
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Prophylaxis, Venous Thromboembolism, Prevention
Interventions
Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Long Beach, California • Orange, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 31, 2011 · Synced Sep 16, 2026, 10:57 AM EDT
Completed No phase listed Observational

Detection of COVID-19 Decompensation

NCT04575532
View directory record Official record
Conditions
Covid19
Interventions
Use of the pinpointIQ solution (physIQ, Inc.)
Device
Lead sponsor
physIQ, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 16, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

NCT01594398
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
Interventions
entinostat, Erlotinib, Exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 16, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

NCT00528619
View directory record Official record
Conditions
Neoplasms
Interventions
Sunitinib, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Sep 16, 2026, 10:57 AM EDT
Recruiting Phase 1Phase 2 Interventional

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

NCT03556228
View directory record Official record
Conditions
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Mesothelioma, Esophageal Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, Salivary Gland Carcinomas, Head and Neck Cancers - Salivary Gland, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Throat, Small Cell Lung Cancer ( SCLC ), Lung Cancer (Locally Advanced or Metastatic), Head and Neck Cancers - Tonsils, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Lip, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oral Cavity, Head and Neck Cancers, Head and Neck Cancers Oropharynx, Head and Neck Cancers Trachea
Interventions
VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
Drug
Lead sponsor
VM Oncology, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
14
States / cities
Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 16, 2026, 10:57 AM EDT
Completed Phase 2 Interventional

Pilot Study in Patients With Symptomatic Steroid-Naive Asthma

NCT00024544
View directory record Official record
Conditions
Asthma
Interventions
anti-IL-4 monoclonal antibody (pascolizumab)
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
18
States / cities
Los Angeles, California • Mission Viejo, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Sep 16, 2026, 10:57 AM EDT
Completed Phase 2 Interventional

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00052052
View directory record Official record
Conditions
Lung Disease, Pulmonary Fibrosis
Interventions
interferon-gamma 1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
20 Years to 79 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Sep 16, 2026, 10:57 AM EDT
Completed Phase 2 Interventional

Pilot Study of the Spiration IBV™ System

NCT00145548
View directory record Official record
Conditions
Emphysema
Interventions
Intra Bronchial Valve
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Sep 16, 2026, 10:57 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders

NCT02156115
View directory record Official record
Conditions
Lymphangiomatosis, Lymphedema, Lymphangiectasia, Pulmonary Lymphangiectasia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 16, 2026, 10:57 AM EDT
Completed No phase listed Observational

Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

NCT00897650
View directory record Official record
Conditions
Lung Cancer
Interventions
DNA/RNA sequencing and expression levels, Protein expression analysis, Lung tumor biopsy, Blood sample
Genetic · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 16, 2026, 10:57 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

NCT06171750
View directory record Official record
Conditions
Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
Interventions
tolododekin alfa, Cemiplimab
Drug
Lead sponsor
Ankyra Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Bethesda, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 16, 2026, 10:57 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease

NCT00465959
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
trospium chloride inhalation powder (TrIP), Placebo
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Timeline
2007
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2013 · Synced Sep 16, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage

NCT00887159
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
Interventions
Cisplatin, Cixutumumab, Etoposide, Laboratory Biomarker Analysis, Vismodegib
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
301
States / cities
Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 205 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 16, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

NCT00712504
View directory record Official record
Conditions
Advanced Solid Tumors, Non Small Cell Lung Cancer
Interventions
sunitinib, docetaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 10, 2008 · Synced Sep 16, 2026, 10:57 AM EDT
Active, not recruiting No phase listed Observational

Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System

NCT06389058
View directory record Official record
Conditions
Severe Asthma
Interventions
Recommendation for the diagnoses and treatment of Severe Asthma
Other
Lead sponsor
San Diego State University
Other
Eligibility
6 Years to 85 Years
Enrollment
31,795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 16, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis

NCT05530278
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Galicaftor, ABBV-576, Navocaftor, Midazolam
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 16, 2026, 10:57 AM EDT
Terminated Phase 4 Interventional Results available

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

NCT04406389
View directory record Official record
Conditions
COVID-19
Interventions
Enoxaparin sodium, Unfractionated heparin, Fondapariniux, Argatroban
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 16, 2026, 10:57 AM EDT
Not yet recruiting Phase 2 Interventional

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

NCT05859217
View directory record Official record
Conditions
Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
Interventions
Cabozantinib, Atezolizumab
Drug
Lead sponsor
Jun Zhang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 16, 2026, 10:57 AM EDT
Completed Not applicable Interventional

Multisystemic Therapy to Reduce Health Disparities in Adolescents With Asthma

NCT00916240
View directory record Official record
Conditions
Asthma
Interventions
Multisystemic Therapy, Home-based, Non-Directive Family Support
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
12 Years to 16 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 16, 2026, 10:57 AM EDT
Terminated Phase 1 Interventional

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

NCT03275597
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Interventions
Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 16, 2026, 10:57 AM EDT
Withdrawn Phase 2 Interventional

A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer

NCT00697060
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Imexon + docetaxel
Drug
Lead sponsor
AmpliMed Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 16, 2026, 10:57 AM EDT
Completed No phase listed Observational

Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy

NCT00442520
View directory record Official record
Conditions
Lung Cancer, Colorectal Cancer, Head and Neck Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Sep 16, 2026, 10:57 AM EDT